{
    "organizations": [],
    "uuid": "ba3c7acb87a815329e16f6345448df147751b695",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aslan-pharmaceuticals-files-for-pr/brief-aslan-pharmaceuticals-files-for-proposed-ipo-in-u-s-idUSFWN1R80ZU",
    "ord_in_thread": 0,
    "title": "BRIEF-‍Aslan Pharmaceuticals Files For Proposed IPO In U.S.​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Aslan Pharmaceuticals Ltd:\n* ‍ASLAN PHARMACEUTICALS FILES FOR PROPOSED INITIAL PUBLIC OFFERING IN U.S.​\n* ‍ASLAN HAS APPLIED TO LIST ITS ADSS ON NASDAQ GLOBAL MARKET UNDER TRADING SYMBOL “ASLN”​\n* ‍LEERINK PARTNERS AND PIPER JAFFRAY & CO. ARE ACTING AS JOINT BOOK-RUNNING MANAGERS FOR THIS OFFERING​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-27T09:27:00.000+03:00",
    "crawled": "2018-03-27T11:52:33.040+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "aslan",
        "pharmaceutical",
        "ltd",
        "pharmaceutical",
        "file",
        "proposed",
        "initial",
        "public",
        "offering",
        "applied",
        "list",
        "adss",
        "nasdaq",
        "global",
        "market",
        "trading",
        "symbol",
        "asln",
        "partner",
        "piper",
        "jaffray",
        "acting",
        "joint",
        "manager",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}